| Writing group member | Employment | Research grant | Other research support | Speakers’ bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|---|---|---|---|---|---|---|---|---|
| Stephen P Juraschek | Harvard Medical School, Beth Israel Deaconess Medical Center | NIH/NHLBI (K23HL135273 and R01 HL153191)† | None | None | None | None | None | None |
| Italo Biaggioni | Vanderbilt University Medical Center | NIH (R01 in autonomic disorders as PI and co-I, R01 HL149386 and R01 HL161095)† | None | None | None | Patent holder for the use of an automated abdominal binder in the treatment of orthostatic hypotension† | Theravance Biopharma†; Takeda*; Regeneron*; Ammeal*; Neurawell* | None |
| Melissa M. Cortez | University of Utah | NIH/NINDS (K23NS105920 and R61NS125153)† | None | None | None | None | None | None |
| John M. Flack | Southern Illinois University School of Medicine | GlaxoSmith Kline†; Indorsia†; ReCor Medical†; Quantam Genomics†; Vascular Dynamics†; Mineralys†; Cincor†; AstraZeneca† (all contracted research) | None | None | Teva† | Amphastar†; Viking Therapeutics†; Orchard Biotechnology† | Ardylex†; ReCor†; GlaxoSmithKline*; AstraZeneca†; Fibrogen†; Amgen*; Janssen* | None |
| Lama Ghazi | University of Alabama at Birmingham | None | None | None | None | None | None | None |
| Rose Anne Kenny | Trinity College Dublin (Ireland) | None | None | None | None | None | None | None |
| Mahboob Rahman | Case Western Reserve University | Bayer (PI for clinical trial, paid to institution)† | None | None | None | None | AstraZeneca* | None |
| Cyndya A. Shibao | Vanderbilt University Medical Center | Theravance (PI)†; NIH (R01 HL150350, R01 HL159203)*; AHA (967054)* | None | Symposia* | None | None | Theravance Biopharma* | None |
| Telisa Spikes | Emory University | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $5000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.